Clinical technology

How to Verify AI Alerts in Oncology Trial Monitoring

What an AI-generated math proof can teach oncology trial teams about tracing monitoring alerts to source records and measuring missed deviations.

By Lampgen Clinical Research

An amber tab lines up across three layers of monitoring records under the headline “Every flag needs a traceable path.”
Editorial illustration for Lampgen Clinical Insights.
A monitoring flagA documented decision
Illustrative workflow from a model alert through source review and escalation.

What the source reported

A monitoring team should be able to trace an AI alert to the source record and the protocol rule before the alert changes how the team prioritizes work. The debate around an AI-generated math proof offers a way to think about that distinction. A result earns trust when reviewers can check precisely what the evidence supports. [1–5]

What the math result changes

OpenAI published a preprint and a Lean formalization in October 2026. The manuscript describes a deterministic algorithm that counts the solutions to a class of true-or-false logic problems in subexponential time as the number of variables grows. In the three-literal case, counting also answers the decision problem known as 3-SAT. A nonzero count means the formula has a solution. If the proof holds, it overturns the Exponential Time Hypothesis, a prediction about how hard that decision can be in the worst case. P versus NP remains open. [2–4]

The Lean release checks a formal statement with a subexponential bound. The manuscript states a sharper bound. An outside working group is examining the result, and Anthropic published a separate argument for a subexponential 3-SAT algorithm. A separate analysis by Fabio Dias and Yvens Lima found that the published guarantee offers a speed advantage over brute force only at input sizes far beyond practical reach in the settings they examined. The near-term impact is a change in how researchers can reason about the limits of algorithms. Any use in drug discovery would still need a method built for the task and benchmarks at realistic sizes. [2–6]

How a late-lab alert can mislead a monitor

Consider an illustrative oncology trial in which a tool flags a pre-dose safety lab as late. The lab feed arrived the next day, but the source record shows the specimen was collected within the protocol window. The alert used the feed timestamp. The clinical research associate (CRA) should verify the collection time, time zone and applicable protocol version. If the protocol also requires results to be available before dosing, that is a separate criterion to verify.

The disposition then follows the evidence. A confirmed deviation follows the study’s documented escalation process. A mapping error goes to the data owner, and the study team checks other sites using the same feed. Record the evidence, the reviewer’s decision and who owns the follow-up. This makes it possible to see why an alert was closed and whether the same issue can recur. [7, 8]

What to measure before relying on AI alerts

Define the tool’s role in writing. For example, it can help prioritize a monitor’s review of possible timing deviations. Specify which records it uses, the approved protocol rules, who reviews the output and which findings must reach the sponsor’s designated escalation pathway. Test it alongside the existing monitoring process, with independent review of samples of flagged and unflagged records. Looking at both groups lets the team estimate missed deviations as well as unnecessary alerts. [7, 8]

Track time from a confirmed finding to appropriate escalation and the staff time spent reviewing flags. Examine results by site and by data feed where the sample supports it. Include sites with different lab vendors and workflows. A tool may look reliable in aggregate while a change to one interface causes recurring errors. Keep a record of model, rule and feed versions so the team knows when to repeat the relevant checks. [7, 8]

What this means for trial teams

A good pilot answers whether the team can find and resolve important deviations sooner while keeping missed events and review burden within limits the sponsor defines in advance. This is where experienced oncology CRAs add value. They understand protocol timing, know what to verify in source, and can document a finding and route it to the appropriate decision-maker. At Lampgen Clinical Research, those are the skills we look for when matching monitors to oncology studies. [7, 8]

Sources

  1. Cade Metz, The New York Times reporting on the Exponential Time Hypothesis, November 6, 2026
  2. OpenAI, Exponential Time Hypothesis preprint, October 25, 2026
  3. OpenAI, scope of the Lean formalization
  4. Impagliazzo, Paturi and Williams, public examination of the ETH result
  5. Dias and Lima, analysis of runtime bounds and constants, October 2026
  6. Anthropic, a separate preprint on 3-SAT
  7. FDA, ICH E6(R3) Good Clinical Practice final guidance
  8. FDA and EMA, Guiding Principles of Good AI Practice in Drug Development
  9. Lampgen Clinical Insights, review of a randomized AI trial notification study
  10. Lampgen Clinical Insights, clinical trial issue closure and risk control

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?